Mogrify appoints Tom Graney as Non-Executive Director, Audit Chair and Capital Markets Advisor
Mogrify, a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, has appointed Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor. He joins senior biopharma industry executives, Dr. Jane Osbourn OBE (Chair) and Dr. Lorenz Mayr, as […]